Like the previously analysed products with valsartan, products with losartan, olmesartan and candesartan that have been investigated do not contain elevated NDMA levels.
Owing to the revision of the TPA and the corresponding implementing ordinances (Therapeutic Products Ordinance Package IV), Swissmedic has adapted the specification documents and forms for authorisation applications.
